Trial Profile

An Exploratory Study to Evaluate the Dose Response-Relationship of Pharmacodynamic Parameters of AryoSeven, in Patients With Hemophilia With Inhibitors

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 12 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eptacog alfa (Primary)
Indications Haemophilia A; Haemophilia B
Focus Therapeutic Use
Sponsors AryoGen Pharmed

Most Recent Events

09 Sep 2022 Status has been changed to completed.
14 Feb 2022 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
14 Feb 2022 Planned primary completion date changed from 1 Apr 2021 to 1 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com